Table 1 Demographic and clinical characteristics between VTE and non-VTE group
Characteristics | With VTE (n = 1647) | Without VTE (n = 107,397) | p |
|---|---|---|---|
Demographics | |||
 Age | 67.0 (55.0–76.0) | 66.0 (54.0–76.0) | 0.569 |
 Male, n (%) | 882 (53.6) | 58,243 (54.2) | 0.583 |
 Body mass index, kg/m2 | 29.1 (24.4–35.2) | 27.5 (23.5–32.9) |  < 0.001 |
 APACHE IV score | 58.0 (43.0–80.0) | 54.0 (40.0–71.0) |  < 0.001 |
 Past history of VTE, n (%) | 457 (27.7) | 4641 (4.3) |  < 0.001 |
 History of cancer, n (%) | 346 (21.0) | 15,722 (14.6) |  < 0.001 |
 Glasgow coma scale | 14.0 (9.0–15.0) | 14.0 (10.0–15.0) | 0.311 |
Principal diagnosis on admission, n (%) | |||
 Cardiovascular condition | 347 (21.1) | 29,364 (27.3) |  < 0.001 |
 Respiratory condition | 576 (35.0) | 17,329 (16.1) |  < 0.001 |
 Gastrointestinal condition | 135 (8.2) | 11,053 (10.3) | 0.005 |
 Renal condition | 22 (1.3) | 1847 (1.7) | 0.233 |
 Neurologic condition | 155 (9.4) | 19,485 (18.1) |  < 0.001 |
 Sepsis | 289 (17.5) | 14,925 (13.9) |  < 0.001 |
 Metabolic condition | 28 (1.7) | 4368 (4.1) |  < 0.001 |
 Trauma | 44 (2.7) | 4901 (4.6) |  < 0.001 |
 Other condition | 51 (3.1) | 4125 (3.8) | 0.118 |
 Diagnosed diseases, n (%) | |||
 Cancer | 220 (13.4) | 4792 (4.5) |  < 0.001 |
 Respiratory failure | 759 (46.1) | 26,110 (24.3) |  < 0.001 |
 Heart failure | 247 (15.0) | 10,064 (9.4) |  < 0.001 |
 End stage renal disease | 56 (3.4) | 3118 (2.9) | 0.234 |
 Sepsis | 444 (27.0) | 15,543 (14.5) |  < 0.001 |
 Treatments, n (%) | |||
 Mechanical ventilation | 688 (41.8) | 40,687 (37.9) | 0.001 |
 Central venous catheter | 298 (18.1) | 15,091 (14.1) |  < 0.001 |
 Vasopressor | 422 (25.6) | 20,636 (19.2) |  < 0.001 |
 Sedative | 630 (38.3) | 40,071 (37.3) | 0.434 |
 Transfusion of blood product | |||
 Platelet | 42 (2.6) | 2301 (2.1) | 0.258 |
 Fresh frozen plasma | 102 (6.2) | 3935 (3.7) |  < 0.001 |
 Packed red blood cells | 199 (12.1) | 10,250 (9.5) | 0.001 |
 Laboratory test results | |||
 Hematocrit, % | 36.5 (31.4–41.3) | 37.4 (32.5–42.0) |  < 0.001 |
 Hemoglobin, g/dl | 11.9 (10.1–13.8) | 12.3 (10.6–14.0) |  < 0.001 |
 Platelet, K/uL | 226.0 (166.0–303.0) | 221.0 (169.0–286.0) | 0.007 |
 While blood cells, K/uL | 12.9 (9.2–18.4) | 12.2 (8.9–16.9) |  < 0.001 |
 Albumin, g/dL | 3.0 (2.6–3.6) | 3.4 (2.8–3.8) |  < 0.001 |
 Blood urea nitrogen, mg/dL | 25.0 (16.0–40.0) | 22.0 (15.0–36.0) |  < 0.001 |
 Creatinine, mg/dL | 1.2 (0.9–2.0) | 1.1 (0.8–1.8) |  < 0.001 |
 INR | 1.2 (1.1–1.5) | 1.4 (1.1–1.9) |  < 0.001 |
 PT, s | 13.3 (11.5–16.2) | 15.9 (13.5–21.4) |  < 0.001 |
 PTT, s | 31.9 (27.5–39.5) | 35.1 (29.4–42.6) |  < 0.001 |
 Total bilirubin, mg/dL | 0.7 (0.5–1.1) | 0.6 (0.4–1.0) |  < 0.001 |
 ALT, U/L | 29.0 (18.0–56.0) | 26.0 (17.0–45.0) |  < 0.001 |
 AST, U/L | 32.0 (20.0–72.0) | 30.0 (20.0–58.0) |  < 0.001 |
VTE prophylaxis method, n (%) | |||
 Pharmacologic prophylaxis | 881 (53.5) | 54,782 (51.0) | 0.046 |
 Graduated compression stockings | 743 (45.1) | 50,133 (46.7) | 0.206 |